Health Care · Pharmaceutical Preparations · NYSE · CIK 78003 · FYE Dec 31 · Prices AT CLOSE 2026-08-20 (USD) Last $27.79 · Day −1.59% · Mkt cap $161.0B · P/E (FY) 20.8× · 1Y +15.2% · Off 52W high −3.3% · Vol (1Y) 23.8% Price2023-08-21 → 2026-08-20 PFE close: $37.0 on 2023-08-21 to $27.8 on 2026-08-20. Split-adj closes · 240 of 6,695 · price returnⓘ At a glance | Short interest2.8% of sh out | | Days to cover4.2d | | 13F net flow (QoQ)+1.44% | | Top-10 13F concentration47.9% | | Next report (est.)2026-11-03 |
SI 2026-07-31 · 13F 2026-Q1ⓘ Key fundamentalsFY 2025 | P/E (FY)20.8× | | Sales (TTM)$63.70B | | Earnings (TTM)$4.33B | | ROE8.9% | | Net margin12.4% | | Debt / equity0.75× | | EPS growth 3Y−37.1% | | Sales growth 3Y−14.8% |
FY ratios · TTM sales/earnings (USD)ⓘ Trailing returns | YTD+15.3% | | 1Y+15.2% | | 3Y−10.5% | | 5Y−26.9% | | 10Y+38.4% | | Since incept. (ann.)+3.7% |
Total return · from 2000-01-03ⓘ Risk | Ann. volatility (1Y)23.8% | | Ann. volatility (3Y)24.4% | | Sharpe (1Y)0.73 | | Sharpe (3Y)−0.03 | | Max drawdown (1Y)−15.7% | | Max drawdown (3Y)−36.2% | | Beta (3Y vs SPY)0.23 |
Daily returns, ann.ⓘ Top institutional holders13F 2026-Q1 | Manager | Shares | Value | % sh out | QoQ |
|---|
| BlackRock, Inc. | 498.3M | $14.0B | 8.76% | +1.1% | | VANGUARD CAPITAL MANAGEMENT LLC | 369.4M | $10.4B | 6.50% | new | | STATE STREET CORP | 301.6M | $8.5B | 5.30% | +0.4% | | GEODE CAPITAL MANAGEMENT, LLC | 133.6M | $3.7B | 2.35% | +2.6% | | VANGUARD PORTFOLIO MANAGEMENT LLC | 116.7M | $3.3B | 2.05% | new | | Fisher Asset Management, LLC | 105.0M | $2.9B | 1.85% | +102.0% | | MORGAN STANLEY | 92.7M | $2.6B | 1.63% | +4.0% | | NORTHERN TRUST CORP | 62.0M | $1.7B | 1.09% | −1.9% |
Δ vs 2025-Q4ⓘ Latest reported quarterslast report 2026-08-04 | Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|
| 2026-06-28 | 2026-08-04 | −$0.04 | −107.8% | $15.03B | +2.6% | | 2026-03-29 | 2026-05-05 | $0.47 | −9.6% | $14.45B | +5.4% | | 2025-12-31 | 2026-02-03 | — | — | $17.56B | −1.2% | | 2025-09-28 | 2025-11-04 | $0.62 | −20.5% | $16.65B | −5.9% |
As-reported XBRL · next 2026-11-03 est.ⓘ Segment mixFY2025 (ended Dec 2025) Biopharma 100% business · TAGGED revenueⓘ Basis & disclosures - EOD closes · nothing imputed or averaged · absent “—”
- As-of differs by block · 13F = US long, 45+d lag, LOWER bound
- Not investment advice · no recommendation, price target or solicitation
- EDGAR + foreign registers · marketstack (licensed EOD) · spzco.com/methodology
| 
